nMRCGP - Make sure you can ace the AKT
Dr Chris Elfes gives a trainer's perspective on how to pass the applied knowledge test. Read more
A study has shown little benefit in screening the whole population for CKD, as promised by prime minister Gordon Brown.
The research involved 6,072 patients, admitted to St George's Hospital in London for cardiovascular problems.
All had estimated glomerular filtration rate (eGFR) measured, showing that 17 per cent had CKD between stages 3 and 5. Nine per cent had CKD-related anaemia.
The researchers compared the prevalence of CKD in the at-risk group with the prevalence recorded in studies on general population CKD screening from the US (4.7 per cent), Norway (4.4 per cent) and China (5.2 per cent).
They concluded that screening at-risk patients 'presents an opportunity for identifying new patients with renal dysfunction'.
But they warned against whole-population screening as 'the practicalities and cost-effectiveness remain unclear'.
Since 2006, the GMS quality framework has included a register of CKD patients. GPs earn quality points for measuring eGFR or serum creatinine levels in diabetics, who are considered at high risk of developing CKD.
'Screening for CKD with eGFR would be a bad idea,' said consultant pathologist at Walsall Hospitals NHS Trust Dr Paul Giles said. 'It is bad at separating people with early CKD from normal people because it has a high false-positive rate, the impact of which worsens the less selective the testing.'
sanjay.tanday@haymarket.com
- QJM Online 2008, live links at healthcarerepublic.com
Dr Chris Elfes gives a trainer's perspective on how to pass the applied knowledge test. Read more
Contributed by Dr Louise Newson, a GP in the West Midlands. Read more
Dr Ben Riley and Dr Jayne Haynes explain what the curriculum is and why it is necessary. Read more
Contributed by Dr Richard Stevens, consultant rheumatologist, Buckinghamshire Hospitals. Read more
Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more
Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more
Wyeth has launched Relistor (methylnaltrexone bromide) for the treatment of opioid-induced constipat... Read more
Thalidomide, under the name of Thalidomide Pharmion is now commercially available in the UK. Read more
The DoH has written to healthcare professionals to call for urgent action to help reduce the risk of... Read more
Comments
Only registered users may comment. Log in now or register for a free account.